Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17953054 | 1.00 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL22783548 | 0.89 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL25112185 | 0.89 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL16618583 | 0.88 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL22783579 | 0.87 | CYP2C9 (0.47) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL17953056 | 0.85 | CYP2C19 (0.84) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL14754237 | 0.85 | CYP2C19 (0.84) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL14754234 | 0.84 | CYP3A4 (0.65) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL14754253 | 0.84 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL24533356 | 0.83 | CYP2C9 (0.46) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | claimed |
| WO-2015051230-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2015-04-09 | — | — | WO | claimed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015051230-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051230-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | CCL5, CCR5, CXCL10 | CYP3A4 4235/4885CYP2C9 4831/4885CYP2D6 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.